Pancreatic Adenocarcinoma Treatment Market to Grow at 13% CAGR During 2026-2030, Led by Pfizer, Roche, Merck & Co., Sanofi, Bristol-Myers Squibb, AstraZeneca, Novartis, and GlaxoSmithKline...
Bristol-Myers Squibb Company (BMY)
Last bristol-myers squibb company earnings: 2/6 07:05 am
Check Earnings Report
US:NYSE Investor Relations:
bms.com/investors.html
Company Research
Source: Yahoo! Finance
health integration, and innovative solutions like irinotecan liposome injections. Rising incidence and need for improved treatments fuel this sector's potential. Pancreatic Adenocarcinoma Treatment Market Pancreatic Adenocarcinoma Treatment Market · GlobeNewswire Inc. Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Pancreatic Adenocarcinoma Treatment Market Report 2026" has been added to ResearchAndMarkets.com's offering. The pancreatic adenocarcinoma treatment market is witnessing remarkable growth, projected to expand from $2.41 billion in 2025 to $2.73 billion in 2026 at a 13.3% CAGR. This escalation is rooted in limited treatment alternatives, reliance on traditional chemotherapy, low early-stage diagnosis, and hospital-centric treatment approaches. Looking ahead, the market is expected to soar to $4.45 billion by 2030, driven by personalized targeted therapies, the rising use of monoclonal antibodies and immunotherapies, digital health solutions, and combination therapy
Show less
Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMY alerts
High impacting Bristol-Myers Squibb Company news events
Weekly update
A roundup of the hottest topics
BMY
News
- Bristol Myers Squibb (BMY) had its "buy" rating reaffirmed by Guggenheim. They now have a $72.00 price target on the stock.MarketBeat
- Bristol Myers Squibb (BMY) had its price target raised by Cantor Fitzgerald from $45.00 to $54.00. They now have a "neutral" rating on the stock.MarketBeat
- How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks [Yahoo! Finance]Yahoo! Finance
- Bristol-Myers Squibb Cancer Moves And Equity Efforts Underpin Valuation Case [Yahoo! Finance]Yahoo! Finance
- Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director [Yahoo! Finance]Yahoo! Finance
BMY
Earnings
- 2/6/26 - Beat
BMY
Sec Filings
- 4/2/26 - Form 4
- 4/2/26 - Form 4
- 4/2/26 - Form 4
- BMY's page on the SEC website